40 related articles for article (PubMed ID: 19955950)
1. A phase II study of everolimus in combination with imatinib for previously treated advanced renal carcinoma.
Ryan CW; Vuky J; Chan JS; Chen Z; Beer TM; Nauman D
Invest New Drugs; 2011 Apr; 29(2):374-9. PubMed ID: 20012337
[TBL] [Abstract][Full Text] [Related]
2. Angiogenesis: A Pivotal Therapeutic Target in the Drug Development of Gynecologic Cancers.
Kasherman L; Liu SL; Karakasis K; Lheureux S
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267430
[TBL] [Abstract][Full Text] [Related]
3. Clinical study of nimotuzumab combined with concurrent radiochemotherapy for treatment of locally advanced cervical cancer.
Chen W; Li T; Wang J; Liang L; Huang D; Yan G; Tian Y; Zhang X; Zhang W
Cancer Manag Res; 2019; 11():8157-8165. PubMed ID: 31564975
[TBL] [Abstract][Full Text] [Related]
4. Involvement of Human Papillomaviruses in Cervical Cancer.
Wang X; Huang X; Zhang Y
Front Microbiol; 2018; 9():2896. PubMed ID: 30546351
[TBL] [Abstract][Full Text] [Related]
5. HER Family Receptors are Important Theranostic Biomarkers for Cervical Cancer: Blocking Glucose Metabolism Enhances the Therapeutic Effect of HER Inhibitors.
Martinho O; Silva-Oliveira R; Cury FP; Barbosa AM; Granja S; Evangelista AF; Marques F; Miranda-Gonçalves V; Cardoso-Carneiro D; de Paula FE; Zanon M; Scapulatempo-Neto C; Moreira MA; Baltazar F; Longatto-Filho A; Reis RM
Theranostics; 2017; 7(3):717-732. PubMed ID: 28255362
[TBL] [Abstract][Full Text] [Related]
6. Mutation analysis of EGFR and its correlation with the HPV in Indian cervical cancer patients.
Qureshi R; Arora H; Biswas S; Perwez A; Naseem A; Wajid S; Gandhi G; Rizvi MA
Tumour Biol; 2016 Jul; 37(7):9089-98. PubMed ID: 26762413
[TBL] [Abstract][Full Text] [Related]
7. A pilot study of nimotuzumab plus single agent chemotherapy as second- or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer.
Cetina L; Crombet T; Jiménez-Lima R; Zapata S; Ramos M; Avila S; Coronel J; Charco E; Bojalil R; Astudillo H; Bazán B; Dueñas-González A
Cancer Biol Ther; 2015; 16(5):684-9. PubMed ID: 25802932
[TBL] [Abstract][Full Text] [Related]
8. New molecular targets against cervical cancer.
Duenas-Gonzalez A; Serrano-Olvera A; Cetina L; Coronel J
Int J Womens Health; 2014; 6():1023-31. PubMed ID: 25525394
[TBL] [Abstract][Full Text] [Related]
9. Angiogenesis and antiangiogenic agents in cervical cancer.
Tomao F; Papa A; Rossi L; Zaccarelli E; Caruso D; Zoratto F; Benedetti Panici P; Tomao S
Onco Targets Ther; 2014; 7():2237-48. PubMed ID: 25506227
[TBL] [Abstract][Full Text] [Related]
10. Folate receptor-targeted liposomes enhanced the antitumor potency of imatinib through the combination of active targeting and molecular targeting.
Ye P; Zhang W; Yang T; Lu Y; Lu M; Gai Y; Ma X; Xiang G
Int J Nanomedicine; 2014; 9():2167-78. PubMed ID: 24855354
[TBL] [Abstract][Full Text] [Related]
11. Emerging biological treatments for uterine cervical carcinoma.
Vici P; Mariani L; Pizzuti L; Sergi D; Di Lauro L; Vizza E; Tomao F; Tomao S; Mancini E; Vincenzoni C; Barba M; Maugeri-Saccà M; Giovinazzo G; Venuti A
J Cancer; 2014; 5(2):86-97. PubMed ID: 24494026
[TBL] [Abstract][Full Text] [Related]
12. Pharmacotherapy options for locally advanced and advanced cervical cancer.
Dueñas-González A; Cetina L; Coronel J; Martínez-Baños D
Drugs; 2010 Mar; 70(4):403-32. PubMed ID: 20205484
[TBL] [Abstract][Full Text] [Related]
13. Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma.
Tsao AS; Liu S; Fujimoto J; Wistuba II; Lee JJ; Marom EM; Charnsangavej C; Fossella FV; Tran HT; Blumenschein GR; Papadimitrakopoulou V; Kies MS; Hong WK; Stewart DJ
J Thorac Oncol; 2011 Dec; 6(12):2104-11. PubMed ID: 21892101
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
Haberler C; Gelpi E; Marosi C; Rössler K; Birner P; Budka H; Hainfellner JA
J Neurooncol; 2006 Jan; 76(2):105-9. PubMed ID: 16205964
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).
Wen PY; Yung WK; Lamborn KR; Norden AD; Cloughesy TF; Abrey LE; Fine HA; Chang SM; Robins HI; Fink K; Deangelis LM; Mehta M; Di Tomaso E; Drappatz J; Kesari S; Ligon KL; Aldape K; Jain RK; Stiles CD; Egorin MJ; Prados MD
Neuro Oncol; 2009 Dec; 11(6):853-60. PubMed ID: 19293394
[TBL] [Abstract][Full Text] [Related]
16. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
Croom KF; Perry CM
Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
[TBL] [Abstract][Full Text] [Related]
17. Control of aggressive fibromatosis by treatment with imatinib mesylate. A case report and review of the literature.
Wcislo G; Szarlej-Wcislo K; Szczylik C
J Cancer Res Clin Oncol; 2007 Aug; 133(8):533-8. PubMed ID: 17453242
[TBL] [Abstract][Full Text] [Related]
18. Lack in efficacy for imatinib mesylate as second-line treatment of recurrent or metastatic cervical cancer expressing platelet-derived growth factor receptor alpha.
Candelaria M; Arias-Bonfill D; Chávez-Blanco A; Chanona J; Cantú D; Pérez C; Dueñas-González A
Int J Gynecol Cancer; 2009 Dec; 19(9):1632-7. PubMed ID: 19955950
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
